<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-205 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-205</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-205</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-8.html">extraction-schema-8</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific brain cell types reported as most susceptible or most resilient in Alzheimer's disease, along with where and when this was observed, how it was measured, quantitative results, proposed mechanisms (including genetic risk enrichment), modifiers (e.g., sex, APOE), contradictions, and any causal/perturbational evidence.</div>
                <p><strong>Paper ID:</strong> paper-4e27a0b3f3002c4115dcd30501fbd5001943b650</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/4e27a0b3f3002c4115dcd30501fbd5001943b650" target="_blank">Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis</a></p>
                <p><strong>Paper Venue:</strong> Biological Psychiatry</p>
                <p><strong>Paper TL;DR:</strong> Understanding the mechanisms underlying the association of these genes with risk for disease will provide the most meaningful targets for therapeutic development to date.</p>
                <p><strong>Cost:</strong> 0.023</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e205.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e205.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific brain cell types reported as most susceptible or most resilient in Alzheimer's disease, along with where and when this was observed, how it was measured, quantitative results, proposed mechanisms (including genetic risk enrichment), modifiers (e.g., sex, APOE), contradictions, and any causal/perturbational evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Neurons (general)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neurons (various neuronal subtypes; e.g., pyramidal neurons)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The paper emphasizes extensive, selective neuronal loss and synaptic loss as core pathological features of AD, with neurofibrillary (tau) pathology strongly correlating with neuronal dysfunction and clinical progression.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type_name</strong></td>
                            <td>Neurons (general; includes pyramidal neurons)</td>
                        </tr>
                        <tr>
                            <td><strong>cell_subtype_or_state</strong></td>
                            <td>selectively vulnerable neurons associated with neurofibrillary tangles</td>
                        </tr>
                        <tr>
                            <td><strong>cell_class</strong></td>
                            <td>neuronal (excitatory and inhibitory neurons)</td>
                        </tr>
                        <tr>
                            <td><strong>markers_or_genes</strong></td>
                            <td>MAPT (tau)/neurofibrillary tangle pathology, APP/Aβ, synaptic markers (general)</td>
                        </tr>
                        <tr>
                            <td><strong>brain_region_and_layer</strong></td>
                            <td>widespread cortical regions and hippocampus (including CA1); laminar detail not systematically specified</td>
                        </tr>
                        <tr>
                            <td><strong>species_or_model</strong></td>
                            <td>human postmortem AD and multiple AD mouse models referenced</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_or_braak</strong></td>
                            <td>clinical AD (general); not tied to a single Braak stage in this review</td>
                        </tr>
                        <tr>
                            <td><strong>susceptibility_label</strong></td>
                            <td>susceptible</td>
                        </tr>
                        <tr>
                            <td><strong>measurement_type</strong></td>
                            <td>neuropathology (histology/immunohistochemistry for plaques/tangles), neuroimaging, and animal model pathology</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_change</strong></td>
                            <td>described as "extensive neuronal loss" and synaptic loss but no specific % loss or counts provided in this paper</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_measured</strong></td>
                            <td>neurofibrillary tangles (tau), amyloid-β plaques, neuritic plaques, synaptic loss, gross atrophy</td>
                        </tr>
                        <tr>
                            <td><strong>associations_with_pathology</strong></td>
                            <td>"Neurofibrillary pathology strongly correlates with neuronal dysfunction and progression of the clinical phase of AD." (no r/p provided)</td>
                        </tr>
                        <tr>
                            <td><strong>spatial_or_proximity_context</strong></td>
                            <td>selective neuronal death in regions burdened by tangles and plaques (hippocampus, cortex); laminar specifics not quantified here</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_hypothesis</strong></td>
                            <td>Amyloid cascade: Aβ aggregation initiates downstream tau pathology leading to synaptic dysfunction and neuronal death; altered APP processing (APP/PSEN mutations) and disrupted lipid/cholesterol pathways (APOE, CLU, ABCA7) modulate neuronal vulnerability.</td>
                        </tr>
                        <tr>
                            <td><strong>ad_gwas_gene_enrichment</strong></td>
                            <td>Several GWAS genes implicated in neuronal APP processing and synaptic/endocytic function (e.g., PICALM, SORL1, BIN1) that may influence neuronal vulnerability; no formal enrichment statistics provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>perturbation_or_causal_evidence</strong></td>
                            <td>Causal evidence cited: dominant mutations in APP, PSEN1, PSEN2 cause early-onset AD with Aβ accumulation and neuronal loss; AD mouse models (APP transgenics) recapitulate deposition and neurodegeneration.</td>
                        </tr>
                        <tr>
                            <td><strong>modifiers_and_risk_factors</strong></td>
                            <td>APOE genotype (ε4) strongly modifies Aβ deposition and is associated with earlier onset and increased pathology; age is a major risk factor.</td>
                        </tr>
                        <tr>
                            <td><strong>comorbid_pathologies</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparisons_to_other_cell_types</strong></td>
                            <td>Contrasted with glial responses (microglial immune-module disruption, astrocytic/clusterin responses); neurons are the main cell type showing loss while glia show activation/dysregulation.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_or_null_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>replication_or_cross_cohort_validation</strong></td>
                            <td>Statement reflects broad neuropathological consensus across human and animal studies; multiple references cited (e.g., refs 1,2 and mouse model studies).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_and_counts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>dataset_or_platform</strong></td>
                            <td>Neuropathological series, neuroimaging cohorts, and transgenic mouse models (no single platform enumerated in this review)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_impact</strong></td>
                            <td>Neuronal and synaptic loss underlie cognitive decline and clinical progression of AD.</td>
                        </tr>
                        <tr>
                            <td><strong>key_evidence_snippet</strong></td>
                            <td>Alzheimer's disease is pathologically defined by extensive neuronal loss and the accumulation of intracellular neurofibrillary tangles and extracellular amyloid plaques in the brain. Neurofibrillary pathology strongly correlates with neuronal dysfunction and progression of the clinical phase of AD.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis', 'publication_date_yy_mm': '2015-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e205.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e205.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific brain cell types reported as most susceptible or most resilient in Alzheimer's disease, along with where and when this was observed, how it was measured, quantitative results, proposed mechanisms (including genetic risk enrichment), modifiers (e.g., sex, APOE), contradictions, and any causal/perturbational evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Hippocampal CA1 neurons (ABCA7)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Hippocampal CA1 neurons (noted for ABCA7 expression)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>ABCA7 is reported to be expressed in hippocampal CA1 neurons but is expressed ~10-fold higher in microglia; ABCA7 risk variants are associated with neuritic plaque burden, implicating ABCA7-related pathways in AD pathology with cell-type expression differences.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type_name</strong></td>
                            <td>Hippocampal CA1 neuron</td>
                        </tr>
                        <tr>
                            <td><strong>cell_subtype_or_state</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cell_class</strong></td>
                            <td>excitatory neuron (CA1 pyramidal neuron)</td>
                        </tr>
                        <tr>
                            <td><strong>markers_or_genes</strong></td>
                            <td>ABCA7 (expression noted in CA1 neurons), APP/Aβ (pathology context)</td>
                        </tr>
                        <tr>
                            <td><strong>brain_region_and_layer</strong></td>
                            <td>hippocampus CA1</td>
                        </tr>
                        <tr>
                            <td><strong>species_or_model</strong></td>
                            <td>human brain expression referenced; ABCA7 functional evidence from mouse models (APP transgenics) cited</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_or_braak</strong></td>
                            <td>AD brains / neuritic plaque burden context (no specific Braak stage specified)</td>
                        </tr>
                        <tr>
                            <td><strong>susceptibility_label</strong></td>
                            <td>mixed/region-specific</td>
                        </tr>
                        <tr>
                            <td><strong>measurement_type</strong></td>
                            <td>mRNA expression quantitation in primary human brain cells (ref cited) and association of GWAS SNPs to neuropathology (neuritic plaque burden)</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_change</strong></td>
                            <td>ABCA7 expression reported as ~10-fold higher in microglia compared to CA1 neurons (ref 65); no neuron loss % reported linked specifically to ABCA7 expression in CA1 here</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_measured</strong></td>
                            <td>neuritic plaque burden (association with ABCA7 SNP rs3764650)</td>
                        </tr>
                        <tr>
                            <td><strong>associations_with_pathology</strong></td>
                            <td>rs3764650 in ABCA7 associated with neuritic plaque burden in AD brains (reference to Shulman et al./GWAS summary; no OR or p-value provided here)</td>
                        </tr>
                        <tr>
                            <td><strong>spatial_or_proximity_context</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_hypothesis</strong></td>
                            <td>ABCA7 may affect AD risk via lipid efflux to APOE-containing particles or by modulating phagocytosis/Aβ clearance; neuronal ABCA7 expression is low relative to microglia, suggesting microglial ABCA7 may be more functionally relevant.</td>
                        </tr>
                        <tr>
                            <td><strong>ad_gwas_gene_enrichment</strong></td>
                            <td>ABCA7 is a GWAS locus for LOAD; its SNPs (e.g., rs3764650, rs4147929) increase LOAD risk and are associated with neuropathology.</td>
                        </tr>
                        <tr>
                            <td><strong>perturbation_or_causal_evidence</strong></td>
                            <td>ABCA7-deficient APP transgenic mice have increased Aβ deposition compared to singly transgenic animals (cited refs 67), indicating ABCA7 loss increases pathology (functional causal evidence, primarily implicating microglial/host clearance functions).</td>
                        </tr>
                        <tr>
                            <td><strong>modifiers_and_risk_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comorbid_pathologies</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparisons_to_other_cell_types</strong></td>
                            <td>ABCA7 expression ~10-fold higher in microglia than in hippocampal CA1 neurons (ref 65).</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_or_null_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>replication_or_cross_cohort_validation</strong></td>
                            <td>Expression and genetic association findings are reported across multiple studies cited; direct replication statistics not provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_and_counts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>dataset_or_platform</strong></td>
                            <td>Gene expression quantitation in primary human brain cells (ref 65) and GWAS/meta-analysis data (multiple large cohorts referenced)</td>
                        </tr>
                        <tr>
                            <td><strong>functional_impact</strong></td>
                            <td>Loss of ABCA7 function in mouse models increases Aβ deposition, implicating ABCA7-mediated phagocytosis/lipid handling in modulation of plaque burden.</td>
                        </tr>
                        <tr>
                            <td><strong>key_evidence_snippet</strong></td>
                            <td>ABCA7 is expressed in hippocampal CA1 neurons and at 10-fold higher levels in microglia (65). rs3764650 in ABCA7 is associated with neuritic plaque burden in AD brains (20). APP transgenic mice that are ABCA7-deficient have increased Aβ deposition compared to the singly transgenic animals (67).</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis', 'publication_date_yy_mm': '2015-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e205.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e205.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific brain cell types reported as most susceptible or most resilient in Alzheimer's disease, along with where and when this was observed, how it was measured, quantitative results, proposed mechanisms (including genetic risk enrichment), modifiers (e.g., sex, APOE), contradictions, and any causal/perturbational evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Microglia (general)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Microglia / brain-resident myeloid cells</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Microglia and immune/microglia-specific gene modules are repeatedly implicated in AD risk and pathogenesis; multiple AD risk genes (TREM2, CD33, ABCA7, INPP5D, MS4A, CR1, HLA) are expressed in microglia and influence Aβ clearance and neuroinflammatory responses.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type_name</strong></td>
                            <td>Microglia</td>
                        </tr>
                        <tr>
                            <td><strong>cell_subtype_or_state</strong></td>
                            <td>immune-activated / disease-associated states implied by disrupted microglial modules; specific DAM nomenclature not used in this review</td>
                        </tr>
                        <tr>
                            <td><strong>cell_class</strong></td>
                            <td>microglia (myeloid lineage)</td>
                        </tr>
                        <tr>
                            <td><strong>markers_or_genes</strong></td>
                            <td>TREM2, CD33, ABCA7, TYROBP (DAP12), INPP5D, MS4A family, HLA-DRB5-DRB1, CR1</td>
                        </tr>
                        <tr>
                            <td><strong>brain_region_and_layer</strong></td>
                            <td>broadly in affected brain regions (cortex, hippocampus); not limited to a single lamina</td>
                        </tr>
                        <tr>
                            <td><strong>species_or_model</strong></td>
                            <td>human postmortem brain datasets (gene-network analysis of 1,647 samples), mouse models, and in vitro microglial/immortalized lines</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_or_braak</strong></td>
                            <td>LOAD/AD in general; associations also noted with CSF tau and neuritic plaque burden</td>
                        </tr>
                        <tr>
                            <td><strong>susceptibility_label</strong></td>
                            <td>susceptible / functionally altered (microglial dysfunction implicated in disease progression)</td>
                        </tr>
                        <tr>
                            <td><strong>measurement_type</strong></td>
                            <td>integrated gene-regulatory network analysis, GWAS, CSF biomarker GWAS, immunohistochemistry, in vitro phagocytosis assays, mouse knockout/transgenic studies</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_change</strong></td>
                            <td>TREM2 R47H carriers: reported ~2-fold increased AD risk (range 1.7–3.4 across studies); ABCA7 expression ~10-fold higher in microglia compared to neurons; CD33 minor allele associated with reduced CD33 exon 2 inclusion and reduced insoluble Aβ42 (no absolute values provided in review).</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_measured</strong></td>
                            <td>amyloid-β plaque burden (insoluble Aβ42), neuritic plaques, CSF tau, brain atrophy</td>
                        </tr>
                        <tr>
                            <td><strong>associations_with_pathology</strong></td>
                            <td>CD33+ microglia positively correlated with insoluble Aβ42 and plaque burden (ref 88); ABCA7 SNP associated with neuritic plaque burden; TREM2 variants associated with increased brain atrophy and CSF tau in cited studies.</td>
                        </tr>
                        <tr>
                            <td><strong>spatial_or_proximity_context</strong></td>
                            <td>microglia are present at/near plaques; CD33+ microglia associated with plaques (immunohistochemical correlation reported).</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_hypothesis</strong></td>
                            <td>Microglial receptors and transporters regulate phagocytosis and inflammation: TREM2 promotes phagocytosis and suppresses inflammation via DAP12/TYROBP; CD33 is inhibitory (ITIM) and reduces Aβ phagocytosis; ABCA7 enhances phagocytosis and lipid handling; disruption of these pathways impairs Aβ clearance and alters neuroinflammatory responses.</td>
                        </tr>
                        <tr>
                            <td><strong>ad_gwas_gene_enrichment</strong></td>
                            <td>Multiple AD GWAS and sequencing hits map to microglial/immune genes (TREM2, CD33, ABCA7, INPP5D, MS4A, HLA-DRB5-DRB1); gene-network analysis (n=1,647 samples) identified immune/microglial modules as disrupted in AD (ref 12).</td>
                        </tr>
                        <tr>
                            <td><strong>perturbation_or_causal_evidence</strong></td>
                            <td>Functional/causal evidence cited: TREM2 rare coding variants (e.g., R47H) increase AD risk; ABCA7 knockout in APP transgenic mice increases Aβ deposition (ref 67); CD33 expression in microglial cell lines inhibits Aβ phagocytosis and exon 2-lacking CD33 abolishes this inhibition (ref 88).</td>
                        </tr>
                        <tr>
                            <td><strong>modifiers_and_risk_factors</strong></td>
                            <td>Some risk variants show interactions (e.g., certain CR1 SNP associated with risk in APOEε4 carriers cited); APOE genotype broadly modifies Aβ deposition and may modulate microglial responses but microglia-specific modifier analyses not detailed here.</td>
                        </tr>
                        <tr>
                            <td><strong>comorbid_pathologies</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparisons_to_other_cell_types</strong></td>
                            <td>Expression of several risk genes (e.g., ABCA7, CD33, TREM2) is enriched in microglia relative to neurons; microglial immune-module disruption highlighted as a central non-neuronal feature.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_or_null_findings</strong></td>
                            <td>CD33 GWAS signal (rs3865444) failed to reach genome-wide significance in the largest meta-analysis (ref 6), although functional biology supports involvement.</td>
                        </tr>
                        <tr>
                            <td><strong>replication_or_cross_cohort_validation</strong></td>
                            <td>Multiple independent genetic, expression, and functional studies cited across cohorts and models support microglial involvement (e.g., GWAS hits, sequencing of TREM2, gene-regulatory network of 1,647 samples).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_and_counts</strong></td>
                            <td>Gene-regulatory network constructed from 1,647 AD and control brain samples (ref 12); other studies vary in size (not enumerated here).</td>
                        </tr>
                        <tr>
                            <td><strong>dataset_or_platform</strong></td>
                            <td>Integrated network analyses (bulk brain transcriptomes), GWAS/meta-analyses, immunohistochemistry, in vitro assays, mouse genetic models</td>
                        </tr>
                        <tr>
                            <td><strong>functional_impact</strong></td>
                            <td>Impaired microglial phagocytosis and dysregulated inflammatory signaling are proposed to reduce Aβ clearance, increase plaque burden, and contribute to neurodegeneration and cognitive decline.</td>
                        </tr>
                        <tr>
                            <td><strong>key_evidence_snippet</strong></td>
                            <td>A recent study constructed gene-regulatory networks from 1,647 AD and control brain samples to demonstrate that networks involved in immune-and microglia-specific modules are disrupted in AD brains (12). TYROBP was identified as a key regulator in a module of genes involved in pathogen phagocytosis (12).</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis', 'publication_date_yy_mm': '2015-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e205.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e205.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific brain cell types reported as most susceptible or most resilient in Alzheimer's disease, along with where and when this was observed, how it was measured, quantitative results, proposed mechanisms (including genetic risk enrichment), modifiers (e.g., sex, APOE), contradictions, and any causal/perturbational evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CD33+ microglia</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CD33-expressing microglia (microglial inhibitory receptor)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>CD33 is a microglial sialic-acid binding receptor whose expression is increased in AD brains and whose activity inhibits microglial Aβ phagocytosis; genetic variants that reduce full-length CD33 or exon 2 inclusion are associated with reduced insoluble Aβ and lower AD risk in some studies.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type_name</strong></td>
                            <td>CD33+ microglia</td>
                        </tr>
                        <tr>
                            <td><strong>cell_subtype_or_state</strong></td>
                            <td>CD33-high (inhibitory) microglial state versus exon-2-skipped CD33 isoform state</td>
                        </tr>
                        <tr>
                            <td><strong>cell_class</strong></td>
                            <td>microglia (myeloid)</td>
                        </tr>
                        <tr>
                            <td><strong>markers_or_genes</strong></td>
                            <td>CD33 (full-length and exon-2-lacking isoforms), ITIM domain signaling components</td>
                        </tr>
                        <tr>
                            <td><strong>brain_region_and_layer</strong></td>
                            <td>observed in AD brain tissue (plaques/affected cortical regions), specific laminar detail not provided</td>
                        </tr>
                        <tr>
                            <td><strong>species_or_model</strong></td>
                            <td>human postmortem AD tissue; immortalized microglial cell lines used in functional assays</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_or_braak</strong></td>
                            <td>associated with more advanced cognitive decline and increased insoluble Aβ/plaque burden in AD brains (stage not numerically specified)</td>
                        </tr>
                        <tr>
                            <td><strong>susceptibility_label</strong></td>
                            <td>susceptible / deleterious state (CD33 activity reduces beneficial Aβ clearance)</td>
                        </tr>
                        <tr>
                            <td><strong>measurement_type</strong></td>
                            <td>mRNA expression in brain tissue, immunohistochemistry (CD33+ microglia correlated with plaques), in vitro phagocytosis assays in immortalized microglial cells, splicing quantitative analysis tied to SNPs</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_change</strong></td>
                            <td>Genetic variant rs3865444 associated with increased exon 2 skipping and reduced CD33 full-length expression; minor allele associated with reduced insoluble Aβ42 in AD brains (no absolute % provided in review).</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_measured</strong></td>
                            <td>insoluble Aβ42 levels, amyloid plaque burden</td>
                        </tr>
                        <tr>
                            <td><strong>associations_with_pathology</strong></td>
                            <td>CD33-positive immunoreactive microglia are positively correlated with insoluble Aβ42 and plaque burden in AD brains (ref 88); rs3865444 associated with reduced insoluble Aβ42.</td>
                        </tr>
                        <tr>
                            <td><strong>spatial_or_proximity_context</strong></td>
                            <td>CD33+ microglia correlated spatially with plaques (immunohistochemical correlation reported).</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_hypothesis</strong></td>
                            <td>CD33 activation inhibits microglial phagocytosis via ITIM signaling, decreasing Aβ uptake and clearance and thereby promoting amyloid accumulation.</td>
                        </tr>
                        <tr>
                            <td><strong>ad_gwas_gene_enrichment</strong></td>
                            <td>CD33 locus identified in LOAD GWAS (initial studies); variant rs3865444 implicated in exon 2 splicing and microglial activation state.</td>
                        </tr>
                        <tr>
                            <td><strong>perturbation_or_causal_evidence</strong></td>
                            <td>In vitro: Aβ phagocytosis is inhibited in immortalized microglial cells expressing full-length CD33; that inhibition is abolished in cells expressing CD33 lacking exon 2 (functional perturbation evidence). Genetic association and isoform-specific effects provide human-correlative causality but no in vivo CD33 knockout causal data are detailed in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>modifiers_and_risk_factors</strong></td>
                            <td>rs3865444 modulates exon 2 splicing; APOE interaction not specifically described for CD33 in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>comorbid_pathologies</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparisons_to_other_cell_types</strong></td>
                            <td>CD33 expression is microglia-specific in brain tissue examined; microglia express CD33 whereas neurons do not (as described in cited studies).</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_or_null_findings</strong></td>
                            <td>rs3865444 failed to reach genome-wide significance in the largest meta-analysis of 74,046 individuals (ref 6), although functional data support a role.</td>
                        </tr>
                        <tr>
                            <td><strong>replication_or_cross_cohort_validation</strong></td>
                            <td>Functional and expression findings cited from multiple groups (refs 87,88) though GWAS-level replication is mixed.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_and_counts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>dataset_or_platform</strong></td>
                            <td>Immunohistochemistry on human brain tissue, in vitro microglial cell line assays, splicing/expression analyses in human brain samples</td>
                        </tr>
                        <tr>
                            <td><strong>functional_impact</strong></td>
                            <td>CD33-mediated inhibition of microglial phagocytosis likely reduces Aβ clearance and increases plaque burden, linking this microglial state to worse amyloid pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>key_evidence_snippet</strong></td>
                            <td>Aβ phagocytosis is inhibited in immortalized microglial cells expressing CD33, and this effect is abolished in cells expressing CD33 lacking exon 2 (88). The minor allele of rs3865444 is associated with reduced CD33 mRNA expression and insoluble Aβ42 in AD brains (88). CD33 positive immunoreactive microglia are also positively correlated with insoluble Aβ42 and plaque burden in AD brains (88).</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis', 'publication_date_yy_mm': '2015-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e205.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e205.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific brain cell types reported as most susceptible or most resilient in Alzheimer's disease, along with where and when this was observed, how it was measured, quantitative results, proposed mechanisms (including genetic risk enrichment), modifiers (e.g., sex, APOE), contradictions, and any causal/perturbational evidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>TREM2+ microglia (TREM2 R47H)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>TREM2-expressing microglia (including carriers of TREM2 rare variants such as R47H)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>TREM2 is a microglial receptor that stimulates phagocytosis and suppresses inflammation; rare coding variants (notably R47H) increase risk for LOAD and are associated with greater brain atrophy and altered CSF tau in cited studies, implicating TREM2-modulated microglial function in AD pathogenesis.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type_name</strong></td>
                            <td>TREM2+ microglia</td>
                        </tr>
                        <tr>
                            <td><strong>cell_subtype_or_state</strong></td>
                            <td>TREM2-competent (phagocytic/anti-inflammatory) vs TREM2-loss-of-function variant states</td>
                        </tr>
                        <tr>
                            <td><strong>cell_class</strong></td>
                            <td>microglia (myeloid)</td>
                        </tr>
                        <tr>
                            <td><strong>markers_or_genes</strong></td>
                            <td>TREM2 (including R47H variant), DAP12/TYROBP (signaling adaptor)</td>
                        </tr>
                        <tr>
                            <td><strong>brain_region_and_layer</strong></td>
                            <td>observed in AD brains broadly; TREM2 variant carriers show more extensive global brain atrophy (MRI) in cited study</td>
                        </tr>
                        <tr>
                            <td><strong>species_or_model</strong></td>
                            <td>human genetic sequencing studies, human MRI data for atrophy comparisons; mouse/in vitro studies referenced re: TREM2 biology</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_or_braak</strong></td>
                            <td>LOAD / sporadic AD context; associations with CSF tau reported (ref 15), stage specifics not provided</td>
                        </tr>
                        <tr>
                            <td><strong>susceptibility_label</strong></td>
                            <td>susceptible (loss-of-function TREM2 variants increase risk and are associated with worse neurodegeneration)</td>
                        </tr>
                        <tr>
                            <td><strong>measurement_type</strong></td>
                            <td>human genetic sequencing (rare variant burden), MRI measures of atrophy, CSF biomarker associations, biochemical studies of receptor processing (γ-secretase cleavage), and references to functional microglial roles</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_change</strong></td>
                            <td>TREM2 R47H (rs75932628) reported to increase LOAD risk approximately two-fold in several studies (range reported across studies: 1.7–3.4-fold); TREM2 variant carriers with AD have more extensive brain atrophy than non-carriers (no absolute mm3 or % provided in review).</td>
                        </tr>
                        <tr>
                            <td><strong>pathology_measured</strong></td>
                            <td>brain atrophy (MRI), CSF tau levels, amyloid/tau biomarkers (associations cited)</td>
                        </tr>
                        <tr>
                            <td><strong>associations_with_pathology</strong></td>
                            <td>TREM2 R47H carriers reported to have increased brain atrophy (ref 104) and regionally altered biomarker levels; variants in the TREM2 region associated with CSF tau levels (ref 15).</td>
                        </tr>
                        <tr>
                            <td><strong>spatial_or_proximity_context</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_hypothesis</strong></td>
                            <td>TREM2 promotes microglial phagocytosis and suppresses inflammatory responses via TYROBP/DAP12 signaling; rare variants likely impair clearance of protein aggregates and dysregulate neuroinflammation, leading to increased neurodegeneration.</td>
                        </tr>
                        <tr>
                            <td><strong>ad_gwas_gene_enrichment</strong></td>
                            <td>TREM2 harbors rare coding variants with moderate effect sizes identified by sequencing studies (not classical common-variant GWAS hits but significant in burden/rare-variant studies).</td>
                        </tr>
                        <tr>
                            <td><strong>perturbation_or_causal_evidence</strong></td>
                            <td>Genetic evidence: homozygous TREM2 mutations cause recessive dementia syndromes; heterozygous rare missense variants (e.g., R47H) increase AD risk (~2x). Biochemical: TREM2 is cleaved by γ-secretase after trafficking to the surface (ref 105) which may regulate its function.</td>
                        </tr>
                        <tr>
                            <td><strong>modifiers_and_risk_factors</strong></td>
                            <td>TREM2 variant risk estimates vary between studies (range 1.7–3.4 fold); TREM2 variants also associated with risk for other neurodegenerative diseases (Parkinson's, FTD, ALS in cited work). Specific interactions with APOE not elaborated in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>comorbid_pathologies</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparisons_to_other_cell_types</strong></td>
                            <td>TREM2 is a microglia-expressed receptor; microglial module disruption (including TYROBP/DAP12) places TREM2 centrally in microglial network dysfunction relative to other cell types.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_or_null_findings</strong></td>
                            <td>Magnitude of R47H-associated risk varies across studies (reported range 1.7–3.4-fold in different cohorts; some debate in literature cited).</td>
                        </tr>
                        <tr>
                            <td><strong>replication_or_cross_cohort_validation</strong></td>
                            <td>Multiple sequencing and population studies replicated association of TREM2 rare variants (e.g., refs 9,10) though effect-size estimates vary.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_and_counts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>dataset_or_platform</strong></td>
                            <td>Whole-exome/targeted sequencing cohorts, MRI cohorts for atrophy analysis, CSF biomarker association studies</td>
                        </tr>
                        <tr>
                            <td><strong>functional_impact</strong></td>
                            <td>TREM2 rare-variant carriers show greater atrophy and altered biomarker profiles; TREM2 biology supports a role in impaired microglial clearance of aggregates and dysregulated inflammation contributing to neurodegeneration.</td>
                        </tr>
                        <tr>
                            <td><strong>key_evidence_snippet</strong></td>
                            <td>The most common variant in European-descent populations, R47H (rs75932628), is reported to increase LOAD risk approximately two fold (9, 10, 97-99). TREM2 mutation carriers with AD have more extensive brain atrophy than non-carriers with AD (104).</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis', 'publication_date_yy_mm': '2015-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta <em>(Rating: 2)</em></li>
                <li>TREM2 variants in Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Variant of TREM2 associated with the risk of Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>